ENZALUTAMIDA ACCORD 40mg capsule me medication leaflet

L02BB04 enzalutamide • Antineoplastic and immunomodulating agents | Hormone antagonists and related agents | Anti-androgens

Enzalutamide is a medication used to treat advanced or metastatic prostate cancer. It works by blocking the effect of androgens, hormones that stimulate the growth of prostate cancer cells. Enzalutamide is usually taken as tablets, as directed by the oncologist.

Treatment with enzalutamide requires careful monitoring, as side effects or interactions with other medications may occur. It is important for patients to follow the treatment schedule and inform the doctor about any new or unusual symptoms.

Side effects may include fatigue, high blood pressure, headaches, sleep disturbances, diarrhea, or loss of appetite. In rare cases, seizures or severe allergic reactions may occur.

Enzalutamide is an effective option for patients with advanced prostate cancer, but it requires constant medical supervision to ensure the effectiveness and safety of the treatment. Collaboration with the medical team is essential for therapy success.

General data about ENZALUTAMIDA ACCORD 40mg

Substance: enzalutamide

Date of last drug list: 01-08-2024

Commercial code: W70363002

Concentration: 40mg

Pharmaceutical form: capsule me

Quantity: 112

Product type: generic

Prescription restrictions: P-RF - Medicines prescription that is retained in the pharmacy (not renewable).

Marketing authorisation

Manufacturer: ACCORD HEALTHCARE POLSKA SP. Z O.O. - POLONIA

Holder: ACCORD HEALTHCARE POLSKA SP. Z O.O. - POLONIA

Number: 15505/2024/02

Shelf life: 2 years

Pharmaceutical forms available for enzalutamide

Concentrations available for enzalutamide

40mg, 80mg

Other substances similar to enzalutamide